Nanoform Finland Plc, the medicine performance-enhancing company, today announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA TM 1, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.
To read this press release, click this text.
To learn more about Drug Delivery and the PODD Conference, please visit drug-delivery.org.
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.